Majestic Announces Normal Course Issuer Bid streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Knight Therapeutics Reports First Quarter 2021 Results
Knight Therapeutics Inc. a leading pan-American specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2021 Highlights Financials Revenues were $46,069, an increase of $230 or 1% over prior year. Gross margin generated of …
Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.
Trican Well Service Ltd.: Trican Reports First Quarter Results for 2021
Trican or the
Company ) is pleased to announce its first quarter results for 2021. The following news release should be read in conjunction with Management s Discussion and Analysis ( MD&A ), the unaudited interim consolidated financial statements and related notes of Trican for the three months ended March 31, 2021, as well as the Annual Information Form for the year ended December 31, 2020. All of these documents are available on SEDAR at www.sedar.com.
HIGHLIGHTS
Consolidated revenue from continuing operations was $148.0 million in Q1 2021, a 23% decrease compared to Q1 2020.
Net profit from continuing operations for Q1 2021 was $1.7 million (Q1 2020 - net loss from continuing operations of $154.5 million). The year-over-year improvement in Q1 2021 compared to Q1 2020 primarily related to reduced impairments of $0.1 million (Q1 2020 - $151.7 million).
(1) of $17.8 million ($0.43 per share
(1)) for the quarter ended March 31, 2021 which was up 9% from royalty revenue of $16.3 million ($0.39 per share) reported in Q1 2020.
Adjusted EBITDA
(1) for the quarter was $14.6 million or $0.35 per share, up 15% from Adjusted EBITDA of $12.7 million ($0.30 per share
(1)) in Q1 2020. The adjusted EBITDA margin for the quarter was 82%.
Adjusted operating cash flow of $8.8 million or $0.21 per share is down by 33% from the comparable quarter last year mainly because of the deferred timing of corporate tax installments during the prior year period.
Net earnings in Q1 2021 are $11.8 million, and on an adjusted basis are $6.3 million or $0.14 per share compared to $3.4 million or $0.08 per share of adjusted earnings in Q1 2020. The main adjusting items in the current quarter are a $0.09 gain on fair value of a derivative (due to increases in unrealized value of warrants in the junior equity portfolio) and a reversal of an impairment charge re
Belgravia Hartford Capital Inc: BELGRAVIA HARTFORD Announces Update on Normal Course Issuer Bid
Toronto, Ontario (Newsfile Corp. - May 7, 2021) - BELGRAVIA HARTFORD CAPITAL INC. (CSE: BLGV) ( Belgravia Hartford , Belgravia or the Company ) previously announced the commencement of a Normal Course Issuer Bid (
NCIB ) on February 23, 2021. In accordance with the NCIB, Belgravia may acquire up to 5% of its issued and outstanding common shares representing 2,008,963 shares. The Company has appointed Leede Jones Gable to coordinate and facilitate its NCIB purchases. The NCIB will terminate on the earlier of February 23, 2022 and the date on which the maximum number of Common Shares that can be acquired pursuant to the NCIB have been purchased. Any common shares purchased pursuant to the NCIB will be cancelled by the Company.